Drug Combination Details
| General Information of the Combination (ID: C08819) | |||||
|---|---|---|---|---|---|
| Name | Honokiol NP Info | + | Doxorubicin Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Breast cancer
[ICD-11: 2C60]
|
Investigative | [1] | ||
|
Uterine Sarcoma
[ICD-11: 2B5F]
|
Investigative | [2] | |||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| In-vitro Model | 4T1 | CVCL_0125 | Malignant neoplasms | Mus musculus | ||
| BCaP-37 | CVCL_0164 | Breast cancer | Homo sapiens | |||
| MCF-7 | CVCL_0031 | Invasive breast carcinoma | Homo sapiens | |||
| In-vivo Model | Mouse 4T1 breast cancer cells (1.0*105) were suspended in 0.1 mL of normal saline (NS) and injected subcutaneously in theright axillary fossa of BALB/c mice. | |||||
| Experimental
Result(s) |
Honokiol inhibited the proliferation of 4T1 cells via apoptosis and significantly enhanced the apoptosis of 4T1 cells induced by adriamycin. | |||||
| β. Reversing Drug Resistance by This Combination | ||||||
| Reversing Drug Resistance | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [2] | |||||
| Biological
Regulation |
Increase | Doxorubicin accumulaiton | ||||
| Decrease | GSH content | |||||
| Increase | ROS generation | |||||
| In-vitro Model | MES-SA/Dx5 | CVCL_2598 | Uterine corpus sarcoma | Homo sapiens | ||
| Experimental
Result(s) |
Honokiol adjuvants to doxorubicin could overcome multidrug resistance P-glycoprotein-mediated in uterine sarcoma. | |||||
